. Author manuscript; available in PMC: 2014 Nov 14.

Published in final edited form as: Biol Blood Marrow Transplant. 2010 Nov 30;17(8):1169–1175. doi: 10.1016/j.bbmt.2010.11.020

Table 1.

Patient Characteristics and Treatment Outcomes

Characteristics	No. of Patients (N = 65)
Type of transplant
Haploidentical/cord blood	28/37
Age, years (range)	34 (4–57)
Sex
Male/female	40/25
Diagnosis
AML/MDS	29
ALL	20
NHL/HD	13
CML/MPD	2
CLL	1
Disease status at transplantation
Complete remission (%)	28 (43%)
Conditioning chemotherapy
FMT ± ATG	100%
GVHD prophylaxis
T cell depletion with no posttransplant immunosuppression	28
Tacrolimus-based^*	37
Number of CD34⁺ cells infused, median (× 10⁶/kg)
Haploidentical SCT patients	10.5
Cord blood transplant patients	0.11
Neutrophil engraftment
n (%)	55 (85%)
median time,^† days (range)	16 (5–57)
Platelet engraftment
n (%)	42 (76%)
median time,^‡ days (range)	29 (7%–134)
ALC 1000
n (%)	28 (51%)
median time, days (range)	57 (26%–434)

AML indicates acute myeloid leukemia; MDS, myelodysplastic syndromes; ALL, acute lymphoblastic leukemia; NHL, non-Hodgkin lymphoma; HD, Hodgkin disease; CML, chronic myeloid leukemia; MPD, myeloproliferative disease; CLL, chronic lymphocytic leukemia; FMT, fludarabine, melphalan, and thiotepa conditioning; ATG, antithymocyte globulin; GVHD, graft-versus-host disease; SCT, stem cell transplant; ALC, absolute lymphocyte count; MTX, methotrexate; MMF, mycophenolate mofetil.

Tacrolimus + MTX 22 patients, tacrolimus + MMF 14 patients, tacrolimus alone 1 patient.

^†

Median 13 days for haploidentical and 21 days for cord blood transplant recipients.

^‡

Median 12 days for haploidentical and 35 days for cord blood transplant.